Atrial fibrillation (AF) is a common heart condition that affects about one in three people at some point in their lives. It ...

Bispecific antibodies have altered the multiple myeloma (MM) treatment landscape, but some practices still lack enough familiarity with these therapeutics to deliver them in outpatient settings.

Patients with a common heart rhythm disorder who took an experimental blood-thinning drug had far fewer bleeding episodes ...

A new study highlights that the experimental blood-thinner abelacimab significantly reduces bleeding risks in atrial fibrillation patients compared to standard treatments like rivaroxaban. In trial ...

Subcutaneous injection of abelacimab results in lower levels of free factor XI and significantly fewer bleeding events than ...

Researchers have found that Factor XI inhibitors, such as abelacimab, reduce bleeding risks in atrial fibrillation patients more effectively than standard anticoagulants.

Abelacimab, a factor XI inhibitor, demonstrated a 62–69% reduction in major bleeding compared to rivaroxaban in atrial fibrillation patients at moderate-to-high stroke risk, with comparable safety and ...

For people with atrial fibrillation (Afib), investigational abelacimab proved to be a potent dual factor XI/XIa inhibitor with much lower safety risks compared with a direct oral anticoagulant (DOAC), ...

Researchers evaluated a drug that represents a new class of anticoagulants known as Factor XI inhibitors for treating patients with atrial fibrillation as part of the AZALEA-TIMI 71 Study. The trial ...

Patients with atrial fibrillation are typically prescribed an anticoagulant, or blood thinner, to reduce the risk of stroke, ...

Anthos Therapeutics' abelacimab shows lower bleeding risk vs Xarelto in atrial fibrillation trial, with 62% reduction in ...

Patients with atrial fibrillation are typically prescribed an anticoagulant, or blood thinner, to reduce the risk of stroke, but many may discontinue them or never receive a prescription due to ...